| Bioactivity | Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy[1]. |
| Invitro | Axl-IN-17 在1 μM 的浓度下可以抑制 TYRO3，MER，MET，RON 等多种激酶[1]。Axl-IN-17 在 BaF3/TEL-AXL 细胞中展现出抗增殖活性，IC50 值＜1 nM[1]。Axl-IN-17 (1 nM，2 h) 抑制 AXL 磷酸化和其下游信号通路[1]。 0 --> Axl-IN-17 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Axl-IN-17 （口服，3 mg/kg，每天一次）具有良好的药代动力学特性，半衰期是10.09 小时，AUC 值是59815 ng•h/mL[1]。Axl-IN-17（p.o.，25，50，100 mg/kg，每天一次，共七天）在 AXL 驱动的肿瘤异种小鼠中表现出抗肿瘤效应[1]。AXL-IN-17在雄性Sprague-Dawley鼠体内的药代动力学分析[1]Route |
| Name | Axl-IN-17 |
| Formula | C32H27F2N7O |
| Molar Mass | 563.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lan Y,et al., Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy. Eur J Med Chem. 2024 Feb 5;265:116045. |